Physician profile
Thomas C Robinson
NPI 1942391354
$2,277.57
in general payments reported to CMS, 2019-2025
27 companies · $97.53 in 2025
The $97.53 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $207 · 2021: $368 · 2022: $380 · 2023: $338 · 2024: $194 · 2025: $97.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $610 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $609.90 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $746.08 | 2019-2023 | Liletta |
| Hologic Sales and Service, LLC | $275.95 | 2019-2023 | Coolseal Generator, Acessa Provu System, Aptima |
| Sumitomo Pharma America, INC. | $214.48 | 2023-2024 | Myfembree |
| Astellas Pharma US INC | $149.29 | 2019-2024 | Veozah |
| Mayne Pharma Commercial LLC | $126.80 | 2022 | |
| Exeltis, USA INC. | $103.96 | 2021-2025 | Slynd |
| Urovant Sciences INC | $75.51 | 2021-2022 | |
| Scynexis, INC. | $64.23 | 2022 | |
| Solventum Corporation | $62.78 | 2025 | Prevena |
| Axonics, INC. | $43.11 | 2023 | Axonics |
| Pfizer INC. | $42.97 | 2022-2024 | |
| Myovant Sciences INC. | $40.35 | 2022 | |
| Sage Therapeutics, LLC | $39.77 | 2024-2025 | Zurzuvae |
| Merck Sharp & Dohme LLC | $35.21 | 2019-2021 | |
| Shield Therapeutics INC | $34.97 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $30.31 | 2021 | |
| Therapeuticsmd, INC. | $27.54 | 2019-2021 | |
| Amgen INC. | $25.82 | 2020 | |
| Organon LLC | $21.89 | 2023 | Nexplanon |
| Bard Access Systems, INC. | $19.34 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.83 | 2022 | |
| Duchesnay USA Incorporated | $14.69 | 2019 | |
| Next Science LLC | $14.62 | 2020 | |
| Lilly USA, LLC | $14.26 | 2021 | |
| Lupin INC. | $13.89 | 2019 | |
| Medtronic, INC. | $11.94 | 2021 | |
| Avion Pharmaceuticals | $10.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.